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A B S T R A C T
Extensive use of pyrethroids for malaria control in Africa has led to widespread pyrethroid resistance in the
two major African vectors of malaria An. gambiae and An. funestus. This is often associated with constitutively
elevated levels of cytochrome P450s involved with pyrethroid metabolism and detoxification. P450s have the
capacity to metabolise diverse substrates, which raises concerns about their potential to cause cross-resistance.
A bank of seven recombinant P450s from An. gambiae (CYPs 6M2, 6P2, 6P3, 6P4, 6P5, 9J5) and An. funestus
(CYP6P9a) commonly associated with pyrethroid resistance were screened against twelve insecticides represent-
ing the five major classes of insecticides recommended by WHO for malaria control; permethrin, etofenprox
and bifenthrin (type I pyrethroids), deltamethrin, lambda cyhalothrin and cypermethrin (type II pyrethroids),
DDT (organochlorine), bendiocarb (carbamate), malathion, pirimiphos methyl and fenitrothion (organophos-
phates) and pyriproxyfen (juvenile hormone analogue). DDT was not metabolised by the P450 panel, while
bendiocarb was only metabolised by CYP6P3. Pyrethroids and pyriproxyfen were largely susceptible to metabo-
lism by the P450 panel, as were organophosphates, which are activated by P450s. Primiphos-methyl is increas-
ingly used for malaria control. Examination of the pirimiphos-methyl metabolites generated by CYP6P3 revealed
both the active pirimiphos-methyl-oxon form and the inactive oxidative cleavage product 2-diethylamino-6-hy-
droxy-4-methylpyrimidine. The inhibition profile of CYPs 6M2, 6P2, 6P3, 6P9a and 9J5 was also examined us-
ing diethoxyfluorescein (DEF) as the probe substrate. Bendiocarb was the weakest inhibitor with IC⁠50 >100μM
across the P450 panel, while CYP6M2 showed strongest inhibition by malathion (IC⁠50 0.7μM). The results sug-
gest that P450s present at elevated levels in two major Anopheline vectors of malaria in Africa have the capacity
to metabolise a diverse range of pyrethroid and organophosphate insecticides as well as pyriproxyfen that could
impact vector control.
1. Introduction
Cases of malaria transmitted by Anopheline mosquitoes in Africa
have halved since the millennium due to the use of long-lasting insec-
ticide treated bednets (LLINs) as well as indoor residual spraying (IRS)
of houses and improved drug therapy (Bhatt et al., 2015). Since 2000
over a billion LLINS have been distributed across the continent, how
ever, with pyrethroids being the predominant insecticide class approved
for use with LLINs, pyrethroid resistance is now widespread in An.
gambiae and An. funestus (J Hemingway et al., 2016a) the two major
vectors of malaria. Two alternative classes of insecticide, organochlo-
rines and carbamates, recommended for IRS by the World Health Or-
ganization are increasingly being used for IRS. However, mosquito
populations are already showing resistance to these as well (Ranson
and Lissenden, 2016), most notably in Cote d'Ivoire and Mali
Abbreviations: b⁠5, cytochrome b⁠5; CPR, cytochrome P450 reductase; CYP, cytochrome P450; DEF, diethoxyfluorescein; IRS, indoor residual spray; LLIN, long-lasting insecticide treated
bednets.
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with resistance to all four classes (Cisse et al., 2015; Ranson et al.,
2012). Pyriproxyfen, a juvenile hormone analogue, and chlorfenapyr, a
pyrrole insecticide, are being trialled for use with bednets (Bayili et al.,
2017; Tiono et al., 2015), while novel chemistries are due to enter the
market in the next few years ( ). However, with resistance mechanisms
in African mosquitoes primed by exposure to pyrethroids, early identifi-
cation of potential cross-resistance issues is an important consideration
in the delivery of insecticides for vector control.
A number of different mechanisms can lead to insecticide resis-
tance including target site insensitivity, cuticular thickening, behav-
ioural avoidance and biodegradation (Hemingway et al., 2004; Li et al.,
2006; Wood et al., 2010). The latter is driven by the constitutive over-
expression of detoxifying enzymes (metabolic resistance) and frequently
associated with the overexpression of cytochrome P450 enzymes (CYPs)
(David et al., 2013). In the past decade transcriptome studies have
shown CYPs 6P3 and 6M2 to be commonly over expressed in pyrethroid
resistant populations of An. gambiae (David et al., 2013; Paine and
Brooke, 2016), while CYPs 6P9a, 6P9b and 6M7 in An. funestus are fre-
quently associated with pyrethroid resistance (Coetzee and Koekemoer,
2013; Riveron et al., 2013; Wondji et al., 2009). Since P450s can
metabolise structurally diverse substrates, populations of pyrethroid re-
sistant mosquitoes with constitutively elevated P450 levels may have
the capacity to metabolise other insecticide classes, potentially leading
to cross-resistance. Indeed, CYP6P3 has been shown to metabolise ben-
diocarb (Edi et al., 2014) as well as pyriproxyfen (Yunta et al., 2016)
along with six other P450s associated with pyrethroid resistance (CYPs
6M2, 6P2, 6P3, 6P4, 6P5 and 6Z2) (Yunta et al., 2016). This high-
lights the potential for pyrethroid metabolising P450s to impact vec-
tor control using other classes of insecticides. Conversely, elevated lev-
els of P450 activity could promote negative cross-resistance in metabol-
ically activated organophosphates such as malathion, fenitrothion and
pirimiphos-methyl. This is particularly relevant for pirimiphos-methyl,
which has been reformulated as Actellic® 300CS to increase longevity
on sprayed walls (Kanyangarara et al., 2016; Oxborough et al., 2014;
Rowland et al., 2013) and is now widely used for IRS operations to con-
trol pyrethroid resistant mosquito strains in Africa (Oxborough, 2016).
In vitro screening for drugs metabolised or inhibited by recombinant
P450 enzymes is well established as a means of early identification of
potential P450-mediated drug interactions in vivo (Wienkers and Heath,
2005). Here, we have established a bank of six recombinant P450s that
have been found overexpressed in pyrethroid resistant populations of
An. gambiae (CYPs 6M2, 6P2, 6P3, 6P4, 6P5, 9J5) and one that is fre
quently associated with pyrethroid resistance in An. funestus (CYP6P9a).
They were used to examine the metabolism and inhibition of com-
pounds representing five major classes of insecticides recommended by
WHO for adult mosquito control (Fig. 1). The results provide a profile
of P450-mediated insecticide interactions in vitro that may help inform
the prediction of potential resistance liabilities in the field.
2. Materials and methods
2.1. Reagents
Oligonucleotides were synthesized by Eurofins genomics and en-
zymes for DNA manipulation were supplied by Thermo Scientific. Iso-
propyl-ß-D-thio-galactopyranoside (IPTG), 5-aminolevulinic acid (ALA),
and 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate
(CHAPS) were supplied by Melford (UK). Insecticides were supplied
by ChemService: 1,1,1-trichloro-2,2-di(4-chlorophenyl)ethane (DDT),
(S)-α-cyano-3-phenoxybenzyl (1R,3R)-cis-2,2-dimethyl-3-(2,2-dibro-
movinyl)-cyclopropanecarboxylate (deltamethrin) and 3-phenoxyben-
zyl (1R,S)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecar-
boxylate (permethrin, mixture of isomers). HPLC solvents were supplied
by Fisher Scientific. Other chemicals were obtained from Sigma-Aldrich
unless indicated otherwise.
2.2. Gene cloning
The pCWori+ expression vector was used for the production of An.
gambiae CYPs 6M2 and 6P3, 6P4, 6P5, 9J5 as previously described
(Yunta et al., 2016). The cDNA sequence encoding CYP6P9a (GenBank
ID: AY729661, previously named CYP6P9) was isolated by RT-PCR us-
ing RNA purified from An. funestus FUMOZ as described (Matambo et
al., 2010). Our first attempt to express CYP6P9a used the E. coli ompA
leader sequence and pCW-ori+as previously described for CYP6Z2
(Mclaughlin et al., 2008) were unsuccessful. Therefore we used another
common strategy for P450 expression, which is to replace the natural
P450 amino-terminus with a sequence (MALLLAVF) derived from the
bovine steroid 17 α-hydroxylase (Barnes et al., 1991). To introduce the
amino-terminal 17α modification the 5′-end of CYP6P9a cDNA was am-
plified using KOD DNA polymerase (Novagen) with the forward primer:
5’-TTCATATGGCTCTGTTATTAGCAGTTTTTGCCGCGTTCATCTTCG-
TAG-3′ (NdeI restriction site at the initiation codon, underlined), and
the reverse primer 5′- CGCTCTAGACTA
Fig. 1. Chemical structures of WHO insecticides used in this study.
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CAACTTTTCCACCTTC-3′ (with an XbaI restriction site, underlined). The
resulting 17α-CYP6P9 was ligated into pCWmod1 via NdeI and XbaI to
create pCW::17α-CYP6P9a. The construct was sequenced and the amino
acid sequence matches CYP6P9a (GenBank: ACG68818.1) (Wondji et
al., 2009). A single plasmid expression system for the P450 and CPR was
constructed by ligating the expression cassette (cDNA and tactac pro-
motor) containing the An. gambiae NADPH P450 reductase (CPR) cDNA
from the pACYC:AgCPR plasmid described above into the pCW:P450
expression plasmid. Briefly, the expression cassette containing the pro-
moter and Ag CPR sequence was cut from a pCW based expression vec-
tor with BamHI and ligated into BamHI digested pCW::17α- CYP6P9a.
This yielded a plasmid with the Ag CPR and CYP6P9a expression cas-
settes in a ‘head to tail’ orientation with the CYP6P9a cassette following
the Ag CPR cassette. In the new construct, although the expression of
each of Ag CPR and CYP6P9a is under the control of its own promoter,
the addition of IPTG to the culture induces the expression of both as the
control in each case is a tactac promoter.
2.3. Production of E. coli membranes co-expressing P450 and AgCPR
CYPs 6M2, 6P3 and 6P9a were co-expressed with AgCPR from a sin-
gle plasmid, while CYPs 6P4, 6P5, 9J5 were co-expressed with AgCPR
following co-transformation of competent E. coli DH5α cells with
pCW:P450 plasmid and pACYC:AgCPR. Cultures were supplemented
with 1.0mM 5-aminolevulinic acid (heme precursor) and incubated at
23 °C for 18–24h after 1mM IPTG induction. P450 expression, E. coli
membrane isolation and determination of P450 and AgCPR content
was performed as previously described (Yunta et al., 2016). Samples
were stored in aliquots at −80 °C. An. gambiae cytochrome b⁠5 (b⁠5) was
prepared as described previously to supplement enzyme reactions at a
10:1M ratio, b⁠5:P450 (Stevenson et al., 2011).
2.4. Insecticide metabolism
P450s were tested against the insecticides from the WHO recom-
mended list of insecticides for public health use. Catalytic activity was
assessed by measuring substrate turnover (disappearance of substrate
with time). 10mM stock concentrations of insecticides were prepared in
methanol or acetonitrile and diluted to 10× the assay concentration in
20% (v/v) methanol or acetonitrile immediately before each experiment
to minimise precipitation of insecticide. Standard reactions contained a
final organic solvent concentration of 2% (v/v) with 20μM insecticide,
0.1μM P450, 1.0μM cyt b5 in 200mM Tris-HCl for pH7.4, and NADPH
regeneration components (1mM glucose-6-phosphate (G6P), 0.25mM
MgCl⁠2, 0.1mM NADP⁠+, and 1U/mL Glucose-6-phosphate dehydroge-
nase (G6PDH)). These were incubated for a specified time at 30 °C with
1200rpm orbital shaking and quenched by adding 0.2mL of acetonitrile
or methanol. Samples were then incubated with shaking as before for an
additional 10min before centrifuging at 20,000×g for 5min. 0.15mL of
the supernatant was then transferred to HPLC vials, stored at room tem-
perature and analyzed within 24h. Reactions were performed in tripli-
cate and compared against a negative control with no NADPH regener-
ating system to calculate substrate depletion.
2.5. HPLC analysis
100μL of organic solvent-quenched reaction supernatant was ana-
lyzed by reverse-phase HPLC with a 250mm C18 column (Acclaim 120,
Thermo Scientific) and a mobile phase optimized for each insecticide
(Table S1). The system was set at 23 °C with 1mL/min flow rate ex-
cept for bendiocarb it was performed at 40 °C. Reactions with perme-
thrin, deltamethrin, etofenprox, bifenthrin or bendiocarb were moni-
tored by absorbance at 226nm whereas DDT, malathion, pyriproxyfen,
pirimiphos-methyl and fenitrothion were monitored at 232nm. The in-
secticide was quantified by peak integration (OpenLAB Chromatogra-
phy Data System). Elution times for all insecticides used are summarized
in Table S1. In the case of stereoisomers in the insecticide mix, the in-
secticide concentrations were measured as the total area under the two
peaks.
2.6. Diethoxyfluorescein metabolism and IC⁠50 analysis
Variable ligand concentrations were used for IC⁠50 calculations with
DEF used at ~ K⁠M for each P450 (i.e. 0.5, 1.4, 0.7, 1.0, 3.5 and 0.5μM
for CYP6M2, CYP6P2, CYP6P3, CYP6P4 and CYP9J5 respectively) and
0.1μM P450. For calculation of the kinetic parameters (K⁠M and V⁠max),
each P450 was used at a final concentration of 10nM (1pmol/reaction)
and DEF concentrations in the range: 0, 0.31, 0.63, 1.25, 2.5, 5, 10 and
20μM. DEF reactions were carried out at 25 °C in 50mM KPi at pH7.4
containing 1mM glucose-6-phosphate (G6P), 0.1mM NADP⁠+, 0.25mM
MgCl⁠2, and cytochrome b⁠5 at a 10:1M ratio, b⁠5:P450. NADP⁠+ and G6P
were excluded from the minus NADPH controls. For IC⁠50 analysis, three
replicates of positive and negative control reactions were run for each
P450/substrate combination in opaque white 96-well (flat-based) plates
in triplicate. The Michaelis-Menten and IC⁠50 fitting calculations were
performed using Graphpad Prism 6. Data were fitted to the dose-re-
sponse model and plots with R⁠2 <0.95 were rejected.
2.7. Mass spectrometry analysis for pirimiphos-methyl metabolism
The chromatographic-mass spectrometric analysis was performed on
a high resolution Thermo Q-Exactive mass spectrometer (MS) which
was coupled to a 1290 series Agilent LC system. Separation of pir-
imiphos-methyl and its metabolites was carried out on a Waters Ac-
quity BEH C18 (2.1×50mm; 1.7μm) analytical column using water
(0.1% formic acid) (A) and acetonitrile (0.1% formic acid) (B) as mo-
bile phases in a 12-min gradient program: 0–1min (5% B); 1–8min (5%
B to 100% B); 8–10min (100% B); 10–10.1min (100% B to 5% B);
10.1–12min (5% B). A sample volume of 5ul was injected. Throughout
the chromatographic run time (12min) a mass range of 100–1000m/z
at 35K resolution was monitored in full scan positive ion mode. The
MS conditions for the analysis (heated electrospray capillary tempera-
ture, sheath gas, auxiliary gas flow rate, spray voltage) were constantly
maintained at 320 °C, 55 (arbitrary units), 10 (arbitrary units), 3500V,
respectively.
3. Results
3.1. Profiling insecticide metabolism
CYPs 6P2, 6P4, 6P5 and 9J5 were previously cloned into
pCW-ori+and co-transformed with AgCPR-pACYC for small-scale
(0.1–0.2L) E. coli expression (Yunta et al., 2016); co-expression of An.
gambiae NADPH-cytochrome P450 oxidoreductase (AgCPR) being re-
quired for coupled electron transfer from NADPH to P450 for cataly-
sis. CYPs 6M2, 6P3 and 6P9a were expressed in tandem with AgCPR
from a single pCW-ori+plasmid to facilitate routine larger scale en-
zyme production (10–20L fermentor); these P450s were amongst the
earliest pyrethroid resistance markers to be functionally validated and
most heavily used for in-vitro screening.. The relative P450 contents and
CPR activities are provided in Table S2.
The catalytic activity of the P450s were assessed by measuring in-
secticide turnover against twelve WHO recommended insecticides in
the presence and absence of NADPH. The insecticide classes and in-
dividual active ingredients tested included type I pyrethroids (perme-
thrin, etofenprox and bifenthrin), type II pyrethroids (deltamethrin,
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lambda cyhalothrin and cypermethrin), an organochlorine (DDT), a car-
bamate (bendiocarb), organophosphates (malathion, pirimiphos methyl
and fenitrothion) and a juvenile hormone analogue (pyriproxyfen). A
cut-off value of 20% substrate depletion was used to distinguish true
substrate turnover from baseline variability (Jones and Houston, 2004).
Results of pyrethroid metabolism are presented in Table 1. All
pyrethroid compounds were metabolised to some degree by the P450
panel. Anopheles gambiae CYP6P3 produced >75% substrate depletion
for all pyrethroid substrates. Anopheles funestus CYP6P9a was similar,
apart from lower levels of bifenthrin and lambda-cyhalothrin turnover
(53.4 and 67.1% respectively). CYP6P4 demonstrated strong activity
against deltamethrin, while CYPs 6P2, 6P5 and 9J5 produced lower,
but reproducible deltamethrin turnover (68.4, 47.0 and 58.1% respec-
tively). Permethrin produced similar results except for CYP9J5, which
displayed high activity comparable to CYP6P4. Etofenprox was strongly
metabolised by all except for CYP6P5.
When tested against the other classes of insecticide (Table 2) none
of the P450s showed significant activity against DDT (organochlorine)
while only CYP6P3 metabolised bendiocarb (35% substrate depletion).
An. gambiae CYPs 6M2, 6P2, 6P3, 6P4, 6P5, and 9J5 have previously
been shown to metabolise pyriproxyfen (Yunta et al., 2016). An. fu-
nestus CYP6P9a also metabolised the juvenile growth hormone
(84.34±0.77% depletion) (Table 2). Except for CYP6M2 and pirim-
iphos-methyl (8.5±1.4% depletion) the three organophosphates
malathion, pirimiphos-methyl and fenitrothion were metabolised by all
the P450s tested.
Pirimiphos-methyl is becoming widely used for IRS operations. It
requires P450 activation into the insecticidal pirimiphos-methyl oxon
form to inhibit acetylcholinesterase, but can also undergo P450 medi
ated detoxifying dearylation reactions (Fig. 2). In order to investigate
this further, LC-MS analysis was performed on the products of pirim-
iphos-methyl metabolism generated by An. gambiae CYP6P3 (Fig. 3),
which represents one of the P450s most commonly overexpressed in
pyrethroid resistant populations of An. gambiae (Ingham et al., 2018).
Known metabolites 2-diethylamino-6-hydroxy-4-methylpyrimidine and
its des-N-ethyl analogue, pirimiphos-methyl oxon and des-N-ethylpir-
imiphos-methyl were targeted using accurate mass technology (Roberts
and Hutson, 1999). Extracted ion chromatograms of [M+H]⁠+ indi-
cated the presence of the insecticidal pirimiphos-methyl oxon (m/z
290.1264) and the inactive 2-diethylamino-6-hydroxy-4-methylpyrimi-
dine (m/z 182.1287) although confirmation of metabolite identification
for the latter was limited by a lack of analytical reference standards in
our study (Fig. 3).
3.2. Inhibition screening of WHO insecticide panel
Fluorescent substrate based inhibition screening of P450s is rou-
tinely used in the pharmaceutical industry for investigating drug-drug
interactions with P450s. As well as being a rapid method of screening
for insecticide interactions with mosquito P450s, the relative strengths
of inhibition of insecticides can indicate potential synergistic effects.
The fluorogenic probe DEF was chosen as a general probe as it is
metabolised by all of the P450s apart from CYP6P4 and CYP6P5. (Yunta
et al., 2016). The ability of the panel of insecticides to inhibit the
mosquito P450s was assayed and compared with piperonyl butoxide
(PBO), a P450 inhibitor widely used in insecticide formulations as
a synergist (Table 3). The compounds were categorized according to
their activity as P450 inhibitors as potent (IC⁠50 <1μM), moderate (IC⁠50
1–10μM) and weak inhibitors (IC⁠50 >10μM) (Krippendorff et
Table 1
Pyrethroid metabolism by mosquito P450s.
P450 % Insecticide depletion
Pyrethroids type I Pyrethroids type II
Permethrin Etofenprox Bifenthrin Deltamethrin λ-cyhalothrin Cypermethrin
Single plasmid
CYP6M2⁠a 58.5±2.2 68.8±1.1 38.9±1.6 55.4±1.4 49.4±0.5 36.8±1.8
CYP6P3⁠a 100.0±0.0 99.8±0.3 76.7±0.3 98.2±0.2 83.3±15.4 98.4±0.1
CYP6P9a⁠a 87.8±0.7 98.5±0.2 53.4±1.6 97.0±0.2 67.1±3.1 89.5±2.7
Dual plasmid
CYP6P2 53.8±1.6 75.5±4.2 nd 68.4±4.8 nd nd
CYP6P4 88.5±0.4 94.0±0.9 nd 88.5±1.4 nd nd
CYP6P5 56.8±5.9 24.4±5.5 nd 47.0±1.9 nd nd
CYP9J5 76.9±1.2 98.9±0.2 nd 58.1±4.0 nd nd
nd, not determined.
a Incubation time 2h instead 90min.
Table 2
Non pyrethroid metabolism by P450s.
P450 % Insecticide depletion
DDT Bendiocarb Malathion Pirimiphos-methyl Fenithrothion Pyriproxyfen
Single plasmid
CYP6M2 2.9±2.1 0±11.2 26.8±8.8 8.5±1.4 35.4±10.4 30.93±4.7⁠⁎
CYP6P3 4.1±5.6 35.0±2.5 68.8±8.4 100.0±0.0 58.2±11.7 100.0±0.0⁠⁎
CYP6P9a 3.9±2.3 10.7±23.7 31.0±4.1 42.0±7.0 41.9±10.3 84.34±0.77
Dual plasmid
CYP6P2 5.1±3.7 5.2±1.6 30.3±9.7 50.6±10.1 21.9±9.7 58.03±1.4⁠⁎
CYP6P4 1.4±1.5 6.8±4.2 44.4±10.1 47.0±16.2 42.8±14.9 81.63±0.6⁠⁎
CYP6P5 0.6±0.3 7.9±2.9 24.2±3.6 23.6±7.5 33.1±12.1 39.96±1.0⁠⁎
CYP9J5 2.6±2.5 8.1±1.4 66.7±9.2 95.7±2.5 50.7±6.5 24.78±2.1⁠⁎
a Published in Yunta et al. (2016).
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Fig. 2. Metabolism pathway of pirimiphos-methyl. Following an insertion of oxygen into the pirimiphos-methyl molecule, a reactive intermediate collapses (1) by desulfuration, or (2)
by cleavage of the ester linkage leading to PMM-M2 and PMM-M3 respectively. Alternative routes of P450 metabolism of pirimiphos-methyl that can produce other metabolites are not
shown. The oxon form inhibits the AchE by forming covalent bound with a serine residue at the active site. PMM, pirimiphos-methyl; PMM-M2, pirimiphos-methyl; PMM-M3, 2-diethy-
lamino-6-hydroxyl-4-methylpyrimidine and AchE, acetilholinesterase.
Fig. 3. Extracted ion chromatograms [M+H]⁠+ from CYP6P3 membranes. Pirimiphos-methyl parent (PMM P) 7.3min (m/z 306.1036) observed in the presence (+) and absence
(−) of NADPH. Metabolites pirimiphos-methyl oxon (PMM-M2) 5.26min (290.1264) and 2-diethylamino-6methy-4-hydroxy-pyrimidine (PMM-3) 2.0min (m/z 182.1287) observed in the
presence of NADPH. Signals within the extracted ion chromatograms at different retention times correspond to low level background ions and/or electronic spikes.
al., 2007). PBO was the strongest inhibitor with IC⁠50 values ranging
from 0.3μM with CYP6M2 to 3.9μM for CYP9J5. Pyrethroids and DDT
were moderate to weak inhibitors in the range 3–17μM. The inhibition
profile of OP insecticides varied from potent inhibition of CYP6M2 by
malathion (IC⁠50 =0.7μM) to weak inhibition by fenitrothion of CYP9J5
(IC⁠50 =48.9μM). Bendiocarb was the weakest inhibitor producing IC⁠50
values in the range 100 to >1000μM.
4. Discussion
P450s play a key role in the metabolism and disposition of in-
secticides in mosquito vectors of malaria. Since P450s are capable of
metabolising structurally diverse substrates, P450 mediated cross resis-
tance between insecticide classes is a major concern (Edi et al., 2014).
Having recently demonstrated that six An. gambiae P450s (CYPs 6M2,
6P2, 6P3, 6P4, 6P5, and 9J5) associated with pyrethroid resistance can
metabolise pyriproxyfen (Yunta et al., 2016), we have further exam-
ined their ability to metabolise a wider range of insecticides represent
ing five major classes of insecticide recommended by WHO for vector
control. We have also extended the panel of recombinant enzymes to in-
clude CYP6P9a from An. funestus (Matambo et al., 2010; Riveron et al.,
2013; Wondji et al., 2009). Overall, there was limited activity against
DDT and carbamate compounds but extensive enzyme cross-reactivity
against all the pyrethroid and organophosphate compounds tested and
the juvenile hormone inhibitor pyriproxyfen (Yunta et al., 2016).
Deltamethrin and permethrin are the most commonly used
pyrethroids for LLINs. Both were metabolised by An gambiae CYP6M2,
CYP6P3, and An funestus CYP6P9a, consistent with a role in detoxifica-
tion as previously reported (Muller et al., 2008; Riveron et al., 2013;
Stevenson et al., 2011). Furthermore, these P450s were also capable of
metabolising etofenprox, bifenthrin λ-cyhalothrin and cypermethrin to
varying degrees. The orthologues An. gambiae CYP6P3 and An. funes-
tus CYP6P9a, produced particularly high levels of depletion across the
pyrethroid range, with lowest substrate depletion levels observed for
bifenthrin (77 and 53% respectively), although this may be explained
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Table 3
IC⁠50 values (μM) of WHO insecticides.
Insecticide IC⁠50 values (μM)
CYP6M2 CYP6P3 CYP6P9a CYP6P2 CYP9J5
Deltamethrin 4.2⁠a 3.2⁠a 2.6 5.0⁠a 6.1⁠a
Permethrin 8.1⁠a 6.8⁠a 5.7 8.6⁠a 6.5⁠a
λ-Cyhalothrin 6.6 9.6 3.7 4.8 4.2
Cypermethrin 1.5 2.6 4.2 9.8 13.5
Bifenthrin 5.6 3.5 8.5 10.7 2.5
Etofenprox 12.0 8.3 8.1 4.7 8.0
Pirimiphos 4.3 3.0 1.7 14.9 5.3
Malathion 0.7 8.0 1.9 17.6 26.9
Bendiocarb >1000 185.2 102.9 >1000 >1000
DTT 8.7 3.1 3.1 13.4 13.3
Fenitrothion 11.5 22.5 13.0 26.7 48.9
PBO 0.3 2.0 1.2 2.7 3.9
Pyriproxyfen 14.1⁠a 15.8⁠a 9.9 9.9⁠a 19.9⁠a
a Published in Yunta et al. (2016).
by the high levels of CPR contained in these membranes. A further
four An gambiae P450s that are overexpressed in pyrethroid resistant
populations (CYP6P2, CYP6P4, CYP6P5 and CYP9J5) (Edi et al., 2014;
Hemingway et al., 2013; Toé et al., 2015) were confirmed to metabolise
deltamethrin, permethrin and etofenprox, with highest levels of activity
observed with An. gambiae CYP6P4 and CYP9J5. An. arabiensis CYP6P4
has previously been reported to selectively metabolise permethrin but
not deltamethrin (Ibrahim et al., 2016). Since An. gambiae and An.
arabiensis CYP6P4 are identical in amino acid sequence, differences in
substrate metabolism might reflect different cytochrome b5 ratios used
and/or reaction times as we used a high P450: b5 ratio (1:10), and an
extended reaction time (90min). Bifenthrin and λ-cyhalothrin tended to
produce lower turnover values. Both are fluorinated molecules, which
limits sites of P450 metabolism, while bifenthrin is structurally con-
strained by a rigid bi-phenyl alcohol moiety that might limit binding in
a catalytically productive orientation in the P450 active site.
The metabolism of the non-pyrethroid insecticides was varied. None
of the P450s metabolised DDT, while CYP6P3 was the only P450 to
metabolise bendiocarb, as previously demonstrated (Edi et al., 2014).
Most striking was the broad cross-reactivity with organophosphate mol-
ecules. Pirimiphos-methyl, which is becoming widely used for IRS for
malaria control in Africa (Oxborough, 2016), was highly metabolised by
An. gambiae CYP6P3 (100% depletion) and CYP9J5 (96% depletion) as
well as An. funestus CYP6P9a (42% depletion). Mass spectrometry analy-
sis of the products of CYP6P3 metabolism indicated that both the active
pirimiphos-methyl-oxon form may be formed along with the inactive
oxidative cleavage product 2-diethylamino-6-hydroxy-4-methylpyrimi-
dine. Thus, elevated levels of expression of CYP6P3 and other cross-re-
acting P450s could feasibly increase or decrease pirimiphos-methyl in-
secticidal activity depending on the relative rates of production of the
active pirimiphos-methyl-oxon and inactive oxidative cleavage prod-
ucts. At present, it is unclear if CYP6P3 is a positive marker for en-
hanced pirimiphos-methyl activity and mosquito susceptibility or if it
is linked with resistance. This recommends further investigations to
characterize the pharmacokinetic profile of pirimiphos-methyl metab-
olism in relation to mosquito control. It is notable that pyrethroid re-
sistant populations of An. gambiae in western Kenya remain suscepti-
ble to an organophosphate (malathion) (Wanjala et al., 2015), while
pirimiphos-methyl (Actellic® 300CS) is effective against pyrethroid re-
sistant Anopheles populations (Kanyangarara et al., 2016; Rowland et
al., 2013). Conversely, resistance to pyrethroids and pirimiphos-methyl,
as well as bendiocarb and DDT, has recently been de
tected in Anopheline mosquito populations in Tanzania (Kisinza et al.,
2017).
While pyrethroid based LLINs have been integral to malaria con-
trol operations in Africa, the rapid increase in pyrethroid resistance is
driving the use of alternative vector control strategies. This includes
combining active ingredients with different modes of action. Pirim-
iphos-methyl for example is used for IRS alongside deltamethrin and
permethrin impregnated nets (Oxborough, 2016), while new genera-
tion LLINs have been developed that incorporate both permethrin and
pyriproxyfen (Tiono et al., 2018). The majority of the pyrethroid com-
pounds produced moderate inhibition across the P450 range (IC50's
1–10μM), suggesting that pyrethroid-P450 interactions could affect
other active-ingredient biotransformation and potency that merits fur-
ther research.
5. Conclusions
Overall, the in vitro profiling indicates that several Anopheles P450s
associated with elevated levels of pyrethroid metabolism in African
mosquito populations can metabolise at least 4 different insecticide
classes recommended by WHO for malaria control. However, complex
pharmacokinetic factors need to be taken into consideration and fur-
ther research is recommended to identify the factors that influence in-
secticide metabolism and disposition in vivo. Nevertheless, with new
active ingredients being developed for mosquito control in Africa (J
Hemingway et al., 2016a), rapid in vitro profiling could be usefully ap-
plied to flag potential metabolic cross resistance liabilities. Furthermore,
it would be advisable to continue to expand the bank of P450s to in-
clude other metabolic resistance candidates including CYP9K1, a P450
that is evolving strong association with deltamethrin resistance in An.
coluzzii populations in Bioko Island, Equatorial Guinea (Vontas et al.,
2018), An gambiae and An. coluzzii in Cameroon (Fossog Tene et al.,
2013) and An. parensis in Uganda (Mulamba et al., 2014).
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